Jay Clemens
Google’s investment arm has teamed up with laboratory services firm SynapDx to examine the genetic sources of autism disorder through data analytics, Praescient Analytics said Tuesday.
Google Ventures will work with SynapDx to conduct disease genomics research in an effort to develop genetics-based treatment for autism, according to the report.
SynapDx began performing blood-based tests in 2013 to detect early-stage autism spectrum disorder, the report says.
The company identified 55 genes from a list of 489 that have the potential to predict autism in nearly two-thirds of the patients, according Praescient.
Researchers will work to investigate the number of autism genetic roots and how these are linked using network analysis methods, according to Praescient.
